The estimated Net Worth of Prabhavathi Fernandes is at least 17.2 千$ dollars as of 25 May 2021. Prabhavathi Fernandes owns over 33,500 units of Ocugen Inc stock worth over 17,220$ and over the last 5 years he sold OCGN stock worth over 0$. In addition, he makes 0$ as Independent Director at Ocugen Inc.
Sign up
Prabhavathi Fernandes OCGN stock SEC Form 4 insiders trading
Prabhavathi has made over 1 trades of the Ocugen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 33,500 units of OCGN stock worth 31,155$ on 25 May 2021.
The largest trade he's ever made was exercising 33,500 units of Ocugen Inc stock on 25 May 2021 worth over 31,155$. On average, Prabhavathi trades about 3,045 units every 0 days since 2020. As of 25 May 2021 he still owns at least 14,000 units of Ocugen Inc stock.
You can see the complete history of Prabhavathi Fernandes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Prabhavathi Fernandes biography
Dr. Prabhavathi B. Fernandes Ph.D. serves as Independent Director of the Company. Dr. Fernandes has held executive leadership positions at Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving BMS, she founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies. Prior to her retirement in December 2016, she led Cempra, Inc. for 12 years as its founder, CEO and chief scientist. Dr. Fernandes currently serves as the Chairperson of both the National Biodefense Science Board (NBSB) and the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership, a Drugs for Neglected Diseases initiative/World Health Organization (DNDi /WHO) initiative. She received her Ph.D. in Microbiology from Thomas Jefferson University. Our Board believes Dr. Fernandes’ extensive experience in the pharmaceutical and biotechnology space provides her with the qualifications and skills to serve on our Board.
How old is Prabhavathi Fernandes?
Prabhavathi Fernandes is 71, he's been the Independent Director of Ocugen Inc since 2020. There are no older and 16 younger executives at Ocugen Inc.
What's Prabhavathi Fernandes's mailing address?
Prabhavathi's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Insiders trading at Ocugen Inc
Over the last 5 years, insiders at Ocugen Inc have traded over 18,069,176$ worth of Ocugen Inc stock and bought 1,511,356 units worth 684,830$ . The most active insiders traders include Shankar Musunuri、Junge Zhang、Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of 96,347$. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth 100,139$.
What does Ocugen Inc do?
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
What does Ocugen Inc's logo look like?
Complete history of Prabhavathi Fernandes stock trades at Opgen Inc、Ocugen Inc
Ocugen Inc executives and stock owners
Ocugen Inc executives and other stock owners filed with the SEC include:
-
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.,
Co-Founder, Chairman & CEO -
Shankar Musunuri,
Chairman of the Board, Chief Executive Officer -
Sanjay S. Subramanian M.B.A.,
Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec. -
Rasappa Arumugham,
Chief Scientific Officer -
Dr. Uday B. Kompella Ph.D.,
Co-founder & Independent Director -
Junge Zhang,
Independent Director -
Suha Taspolatoglu,
Independent Director -
Manish Potti,
Independent Director -
Ramesh Kumar,
Independent Director -
Uday Kompella,
Independent Director -
Prabhavathi Fernandes,
Independent Director -
Kirsten Castillo,
Independent Director -
Kelly Beck,
Vice President, Investor Relations and Administration and Corporate Secretary -
Vijay Tammara,
Senior Vice President - Regulatory and Quality -
Sanjay Subramanian,
Chief Financial Officer, Chief Accounting Officer, Treasurer -
Michael Shine,
Sr. VP of Commercial -
J. P. Gabriel,
Sr. VP of Manufacturing & Supply Chain -
Dr. Bruce D. Forrest B.S., M.B.A., M.D.,
Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member -
Dr. Arun Upadhyay Ph.D.,
Head of Research, Devel. & Discovery -
Dr. Vijay Tammara,
Sr. VP of Regulatory & Quality -
Zara Gaudioso,
Head of HR -
Ken Inchausti,
Head of Investor Relations & Communications -
Jessica Crespo,
CAO/SVP, Finance -
Daniel Jorgensen,
Chief Medical Officer -
Frank Leo,
Director -
Marna C Whittington,
Director -
Huma Qamar,
Chief Medical Officer -
Arun Upadhyay,
See Remarks